Introduction {#Sec1}
============

Gastric cancer (GC) is the 4th most common malignant tumor and the 3rd leading cause of cancer-related mortality worldwide \[[@CR1]\]. Multiple gastric cancers (MGCs) refer to gastric cancers with two or more cancerous lesions in the stomach \[[@CR2]\]. With the advancement of diagnostic endoscopy techniques and detailed pathological examination of postoperative specimens, the detection of MGC has increased annually \[[@CR3], [@CR4]\]. The incidence of MGC reportedly accounts for 2%--8% of all gastric cancers \[[@CR2]--[@CR6]\]. Whether the clinical and pathological features of MGC are different from those of solitary gastric cancers (SGCs) remain controversial. Eom et al. found that MGCs were more likely to occur in elderly patients, males, individuals with a family history of cancer, cases of upper stomach tumors, and early gastric cancer patients \[[@CR7]\]. However, Borie et al. found that there was no significant difference in the clinical data between MGC and SGC \[[@CR8]\]. Furthermore, little is known about the impact of MGC on the survival of gastric cancer patients, and the effect of adjuvant chemotherapy on their long-term prognoses. Therefore, using a large cohort of GC patients, we aimed at comparing and correlating the differences in clinicopathological data and the impact of postoperative adjuvant chemotherapy on the long-term survival of patients with MGC as compared to those with SGC.

Patients and methods {#Sec2}
====================

Patients selection {#Sec3}
------------------

The clinicopathological data of 4613 patients diagnosed with gastric adenocarcinoma who had radical gastrectomy at the Fujian Medical University Union Hospital (Fuzhou, Fujian, China) from January 2007 to December 2016 were retrospectively analyzed. The inclusion criteria were as follows: (1) preoperatively confirmed diagnosis of GC; (2) no evidence of distant metastasis before surgery; (3) radical gastrectomy (R0 resection); and (4) no records of other additional adjuvant treatments other than adjuvant chemotherapy. The exclusion criteria were as follows: (1) a history of previous malignancy (*n* = 74); (2) a history of previous gastric surgery (*n* = 77); (3) treatment with neoadjuvant chemotherapy (*n* = 140); and (4) pathological T4b stage tumor (*n* = 95); and (5) incomplete clinical and pathological data (*n* = 120). All patients' clinical and pathological data were collected using the Gastric Cancer Clinical Data Management and Analysis System (Lisheng, Guangzhou, Guangdong, China) \[[@CR9]\]. The surgical approach was performed according to the guidelines of the Japanese Society of Gastric Cancer Association \[[@CR10]\]. Each resected specimen was histologically carefully examined by an expert pathologist with an experience of more than 5 years. The histological type, number of examined lymph nodes (eLNs), and number of lymph node metastases were recorded from the postoperative pathological report. This study was approved by the ethics committee of Fujian Medical University Union Hospital and was allocated with the IRB number 2018KY040. Each subject provided signed informed consent before participating to this study.

Definition of MGC {#Sec4}
-----------------

The definition of MGC complied with the criteria proposed by Moertel et al. \[[@CR2]\], which are as follows: (1) each lesion must be pathologically proven to be malignant; (2) all lesions must be separated by areas of microscopically normal gastric wall; and (3) the possibility that one of the lesion represents a local extension of a metastatic tumor must be ruled out beyond reasonable doubt. When multiple gastric lesions infiltrated different depths of the stomach wall, the cancer was defined and staged according to the more advanced lesion (depth of invasion) or according to the larger lesion if the depth of invasion was the same. When multiple gastric lesions had different histological types, the cancer was classified according to the less differentiated type.

Variables and definitions {#Sec5}
-------------------------

Variables included in this study were age, sex, body mass index (BMI), family history, tobacco and alcohol use, the American Society of Anesthesiologists (ASA) score, comorbidities, clinical tumor stage (cT stage), clinical node stage (cN stage), surgical approach, type of gastrectomy, number of eLNs, pathological tumor stage (pT stage), pathological node stage (pN stage), pathological tumor-node-metastasis stage (pTNM stage), tumor size, tumor histological type, postoperative complications, and adjuvant chemotherapy. The patients' BMI were classified into these following categories: \< 18.5, 18.5--24.9 and ≥ 25 kg/m^2^, based on the World Health Organization (WHO) classification standards. Family history for the first- and second-degree relatives was queried and was categorized as absence of family history, family history of GC, and family history of other malignancy. The comorbidities analyzed in this study comprised of hypertension, diabetic mellitus, heart disease (coronary atherosclerotic heart disease, arrhythmia, etc.), pulmonary disease (chronic obstructive pulmonary disease, asthma, pneumonia, etc.), central nervous system disease (cerebrovascular disease, neurodegenerative disease, etc.), liver disease (cirrhosis, hepatitis, etc.), renal disease (chronic kidney disease, nephritis, etc.), anemia, hypoalbuminemia, and hyperthyroidism. The postoperative pathological stage of the tumor was determined according to the eighth edition of the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) staging manual \[[@CR11]\]. The type of gastrectomy was categorized as total gastrectomy, distal gastrectomy, and proximal gastrectomy. The number of eLNs was grouped as ≤ 15 and \> 15 eLNs according to the 4th version of the Japanese gastric cancer treatment guidelines \[[@CR10]\]. Based on the Japanese classification of gastric carcinoma, early GC was defined as lesions confined to the mucosa or submucosa, regardless to the presence of regional lymph node metastasis, while advanced GC was defined as T2-T4 carcinoma without distant metastasis \[[@CR12]\]. Most advanced GC patients were recommended to receive 6--8 cycles of oxaliplatin (Sanofi, Paris, France) plus capecitabine (Roche, Basel, Switzerland) (XELOX regimen) or oxaliplatin plus S-1 (Taiho, Tokyo, Japan) (SOX regimen) chemotherapy regimen \[[@CR13], [@CR14]\]. All treatment cycles were administered every 3 weeks. Oxaliplatin was infused intravenously for 2 h on day 1 at a dose of 130 mg/m^2^. Capecitabine/S-1 was administered orally twice daily from day 1 to 14 (dosage: capecitabine, 2000 mg/m^2^/day; S-1, 80--120 mg/m^2^/day), followed by 1-week rest; after which the next cycle was resumed.

Follow-up {#Sec6}
---------

Follow-up evaluation after surgery generally consisted of clinic visits, serologic chemistry profiles, and computed tomography (CT) scans repeated every 3--6 months for the first 2 years then every 6--12 months for the following 3--5 years, and annually afterwards. The overall survival (OS) time was recorded as from the date of surgery to the last follow-up date, date of death, or date until the end of follow-up (such as loss to follow-up or death due to other diseases). The last date of follow-up was June 2017.

Statistical analysis {#Sec7}
--------------------

Categorical variables were analyzed using the Chi square test or Fisher's exact test, whereas continuous variables were analyzed using the student's *t*-test or the Mann--Whitney U test. The propensity score matching ratio was set to 1:4 ratio to minimize the differences between MGC and SGC due to age, sex, BMI, ASA score, comorbidities, clinical stage, type of gastrectomy, and pathological stage with the nearest neighbor method using R software (version 3.4.2, "MatchIt" and "Foreign" packages, <http://www.r-project.org>) \[[@CR15], [@CR16]\]. The Kaplan--Meier method was used to calculate the time-dependent survival probabilities. The log-rank test was applied for statistical comparisons between survival curves. Univariate and multivariate analysis was performed using the Cox proportional hazards model, and all significant variables (*P* \< 0.05) in the univariate analysis were computed into the multivariate analysis to identify the independent prognostic factors. Statistical analyses were performed using the IBM SPSS software (version 22.0, Chicago, IL, USA) and the R software, all statistical tests were two-sided, and a *P* value \< 0.05 was considered statistically significant.

Results {#Sec8}
=======

Incidence and distribution of the MGC within the stomach {#Sec9}
--------------------------------------------------------

A total of 4107 patients were included in this study, comprising of 133 (3.2%) patients with MGC and 3974 (96.8%) patients with SGC (Fig. [1](#Fig1){ref-type="fig"}). The distribution of MGC in the stomach is shown in Fig. [2](#Fig2){ref-type="fig"}. The MGC lesions of 11 (8.3%) patients were located in the upper third of the stomach, 15 (11.3%) in the middle third, and 32 (24.1%) in the lower third of the stomach. The MGC lesions were identified in more than one locations, namely in the upper and middle third, the upper and lower third, and the middle and lower third of the stomach in 16 (12.0%), 20 (15.0%), and 25 (18.8%) patients, respectively. Further, in 14 (10.5%) patients, the lesions were simultaneously identified in the upper, middle, and lower third of the stomach.Fig. 1Case screening process of this study. *SGC* solitary gastric cancer, *MGC* multiple gastric cancer Fig. 2Distributions of the multiple gastric cancers (MGC). There were 43.7% of the MGC located in only one-third of the stomach (blue circle), 45.8% distributed throughout two-thirds of the stomach (yellow triangle), and the other 10.5% covering more than two third of the stomach (red rhombus)

Comparison of the clinical and pathological data between the MGC and SGC groups before and after propensity score matching {#Sec10}
--------------------------------------------------------------------------------------------------------------------------

Before matching, there were statistically significant differences in the type of gastrectomy (*P* \< 0.001), pT stage (*P* = 0.033), pN stage (*P* = 0.035) and pTNM stage (*P* = 0.041) between the two groups, but no significant differences were observed in the preoperative data, namely, age, sex, BMI, family history, tobacco and alcohol use, ASA score, comorbidities, cT stage, or cN stage (all *P* ≥ 0.05) (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}).Table 1Preoperative clinical characteristics of SGC and MGC in the entire cohort (*n* = 4107) and after propensity score matching (*n* = 665)ParametersEntire cohort (before matching)*P* valuePropensity score matched cohort*P* valueSGC, *n* (%)MGC, *n* (%)SGC, *n* (%)MGC, *n* (%)Age (years)0.1410.968 ≤ 601871 (47.1)54 (40.6)215 (40.4)54 (40.6) \> 602103 (52.9)79 (59.4)317 (59.6)79 (59.4)Sex0.1660.886 Male2924 (73.6)105 (78.9)423 (79.5)105 (78.9) Female1050 (26.4)28 (21.1)109 (20.5)28 (21.1)BMI (kg/m^2^)0.4670.947 BMI \< 18.5385 (9.7)13 (9.8)57 (10.7)13 (9.8) 18.5 ≤ BMI \< 252921 (73.5)103 (77.4)406 (76.3)103 (77.4) BMI ≥ 25668 (16.8)17 (12.8)69 (13.0)17 (12.8)Family history^a^0.2730.269 Absent3736 (94.0)126 (94.7)518 (97.3)126 (94.7) Gastric cancer128 (3.2)6 (4.5)11 (2.1)6 (4.5) Other malignancy110 (2.8)1 (0.8)3 (0.6)1 (0.8)Tobacco use0.7540.965 No2849 (71.7)97 (72.9)389 (73.1)97 (72.9) Yes1125 (28.3)36 (27.1)143 (26.9)36 (27.1)Alcohol use0.4100.532 No3657 (92.0)125 (94.0)507 (95.3)125 (94.0) Yes317 (8.0)8 (6.0)25 (4.7)8 (6.0)ASA score0.1680.641 I1954 (49.2)57 (42.9)241 (45.3)57 (42.8) II1818 (45.7)71 (53.4)269 (50.6)71 (53.4) III193 (4.9)4 (3.0)21 (3.9)4 (3.0) IV9 (0.2)1 (0.8)1 (0.2)1 (0.8)Comorbidities^b^0.4640.715 Absent1226 (30.9)88 (66.2)343 (64.5)88 (66.2) Present2748 (69.1)45 (33.8)189 (35.5)45 (33.8)cT stage0.9200.785 T1--T32074 (52.2)70 (52.6)287 (53.9)70 (52.6) T41900 (47.8)63 (47.4)245 (46.1)63 (47.4)cN stage0.0500.806 N01653 (41.6)44 (33.1)182 (34.2)44 (33.1) N+2321 (58.4)89 (66.9)350 (65.8)89 (66.9)*SGC* solitary gastric cancers, *MGC* multiple gastric cancers, *BMI* body mass index, *ASA* American Society of Anesthesiologists, *cT stage* clinical tumor stage, *cN stage* clinical node stage, *cN0* clinical node-negative, *cN+* clinical node-positive^a^*Family history* presence of cancer within the patients' first- and second- degree relatives^b^*Comorbidities* including hypertension, diabetic mellitus, heart disease (coronary atherosclerotic heart disease, arrhythmia, etc.), pulmonary disease (chronic obstructive pulmonary disease, asthma, pneumonia, etc.), central nervous system disease (cerebrovascular disease, neurodegenerative disease, etc.), liver disease (cirrhosis, hepatitis, etc.), renal disease (chronic kidney disease, nephritis, etc.), anemia, hypoalbuminemia, and hyperthyroidism Table 2Surgical and postoperative pathological characteristics, and treatment of the SGC and MGC of the entire cohort (*n* = 4107) and after propensity score matching (*n* = 665)ParametersEntire cohort (before matching)*P* valuePropensity score matched cohort*P* valueSGC, *n* (%)MGC, *n* (%)SGC, *n* (%)MGC, *n* (%)Surgical approach0.4140.959 Open802 (20.2)23 (17.3)93 (17.5)23 (17.3) Laparoscopic3172 (79.8)110 (82.7)439 (82.5)110 (82.7)Type of gastrectomy\< 0.0011.000 Total2129 (53.6)106 (79.7)424 (79.7)106 (79.7) Distal1782 (44.8)27 (20.3)108 (20.3)27 (20.3) Proximal63 (1.6)0 (0.0)0 (0.0)0 (0.0)Number of eLNs0.5470.514 ≤ 15161 (4.1)4 (3.0)11 (2.1)4 (3.0) \> 153813 (95.9)129 (97.0)521 (97.9)129 (97.0)pT stage0.0330.706 T1983 (24.7)20 (15.0)98 (18.4)20 (15.0) T2446 (11.2)17 (12.8)54 (10.2)17 (12.8) T31165 (29.3)37 (27.8)144 (27.1)37 (27.8) T4a1380 (34.7)59 (44.4)236 (44.4)59 (44.4)pN stage0.0350.909 N01442 (36.3)37 (27.8)157 (29.5)37 (27.8) N1601 (15.1)16 (12.0)73 (13.7)16 (12.0) N2680 (17.1)23 (17.3)86 (16.2)23 (17.3) N31251 (31.5)57 (42.9)216 (40.6)57 (42.9)pTNM stage0.0410.430 Stage I1143 (28.8)25 (18.8)123 (23.1)25 (18.8) Stage II875 (22.0)32 (24.1)107 (20.1)32 (24.1) Stage III1956 (49.2)76 (57.1)302 (56.8)76 (57.1)Tumor size0.2220.843 ≤ 5 cm2652 (66.7)82 (61.7)323 (60.7)82 (61.7) \> 5 cm1322 (33.3)51 (38.3)209 (39.3)51 (38.3)Tumor histological type0.6400.860 Differentiated1150 (28.9)36 (27.1)140 (26.3)36 (27.1) Undifferentiated2824 (71.1)97 (72.9)392 (73.7)97 (72.9)Postoperative complications0.2420.481 Absent3182 (80.1)101 (75.9)419 (78.8)101 (75.9) Present792 (19.9)32 (24.1)113 (21.2)32 (24.1)Adjuvant chemotherapy^a^0.0690.852 No1263 (42.2)38 (33.6)150 (34.6)38 (33.6) Yes1728 (57.8)75 (66.4)284 (65.4)75 (66.4)*SGC* solitary gastric cancers, *MGC* multiple gastric cancers, *eLNs* examined lymph nodes, *pT stage* pathological tumor stage, *pN stage* pathological node stage, *pTNM stage* pathological tumor-node-metastasis stage^a^*Adjuvant chemotherapy* only patients with advanced gastric cancer were analyzed, which included 3104 patients before matching and 547 after matching

After the propensity score matching ratio was set to 1:4, the clinicopathologic data of 133 patients in the MGC group were found comparable with 532 patients in the SGC group (*P* \> 0.05 between all variables) (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}).

Impact of MGC on 5-year OS {#Sec11}
--------------------------

After matching, the median follow-up time of the entire matched cohort was 31 months (range 1--127 months), and the 5-year OS rate was 56.6%. For the MGC and SGC groups, the 5-year OS rates were 48.1% and 58.7%, respectively (*P* = 0.013, Fig. [3](#Fig3){ref-type="fig"}a).Fig. 3Impact of MGC on OS. **a** In all stages (early and advanced) of gastric cancer. The 5-year OS rate was 56.6% for the entire study cohort. For the MGC and SGC groups, the 5-year OS rates were 48.1% and 58.7%, respectively (*P* = 0.013). **b** In the early stage. The 5-year OS rate was 91.2%. For the MGC and SGC groups, the 5-year OS rates were 83.3% and 91.8%, respectively (*P* = 0.852). **c** In the advanced stage. The 5-year OS rate was 49.4%. For the MGC and SGC groups, the 5-year OS rates were 43.0% and 51.1%, respectively (*P* = 0.036). **d** The 5-year OS rates of MGC patients who underwent total gastrectomy and distal gastrectomy were 45.4% and 61.5%, respectively (*P* = 0.114). *MGC* multiple gastric cancers, *SGC* solitary gastric cancers, *OS* overall survival

After stratification based on the stage of the tumor, the 5-year OS rate of the early GC cohort was 91.2%, and no statistically significant difference in the 5-year OS rates between the early MGC (5-year OS, 83.3%) and SGC (5-year OS, 91.8%) were found (*P* = 0.852, Fig. [3](#Fig3){ref-type="fig"}b). The 5-year OS rate for the cohort of advanced GC patients was 49.4%, among which the 5-year OS rates of the advanced MGC and SGC group were 43.0% and 51.1% respectively, and significant differences in survival between the two groups were observed (*P* = 0.036, Fig. [3](#Fig3){ref-type="fig"}c). When stratified by the types of gastrectomy, the 5-year OS rates of MGC patients who underwent total gastrectomy and distal gastrectomy were 45.4% and 61.5%, respectively, but no significant difference in 5-year OS was found (*P* = 0.114, Fig. [3](#Fig3){ref-type="fig"}d).

Univariate and multivariate analysis for OS {#Sec12}
-------------------------------------------

Univariate analysis showed that MGC (*P* = 0.014), age (*P* = 0.029), cT stage (*P* \< 0.001), cN stage (*P* \< 0.001), surgical approach (*P* \< 0.001), type of gastrectomy (*P* \< 0.001), pT stage (*P* \< 0.001), pN stage (*P* \< 0.001), tumor size (*P* \< 0.001), histological subtype (*P* = 0.009), and adjuvant chemotherapy (*P* = 0.032) were correlated with OS. However, on multivariate analysis only MGC (*P* = 0.039), age (*P* = 0.043), pT stage (*P* \< 0.001), pN stage (*P* \< 0.001), and adjuvant chemotherapy (*P* = 0.014) were identified as independent risk factors for OS (Table [3](#Tab3){ref-type="table"}).Table 3Univariate and multivariate analysis to determine the prognostic factors for the overall survival in the matched cohortParametersUnivariate analysis*P* valueMultivariate analysis*P* valueHR (95% CI)HR (95% CI)MGC AbsentRefRef Present1.456 (1.079--1.964)0.0141.378 (1.016--1.870)0.039Age (years) ≤ 60RefRef \> 601.343 (1.03--1.751)0.0291.319 (1.009--1.726)0.043cT stage T1--T3RefRef T42.862 (2.181--3.755)\< 0.0010.931 (0.663--1.307)0.681cN stage N0RefRef N+2.592 (1.882--3.568)\< 0.0011.085 (0.762--1.545)0.652Surgical approach OpenRefRef Laparoscopic0.611 (0.458--0.815)\< 0.0010.777 (0.577--1.048)0.098Type of gastrectomy TotalRefRef Distal0.479 (0.328--0.699)\< 0.0010.794 (0.530--1.187)0.261pT stage\< 0.001\< 0.001 T1RefRef T22.57 (0.996--6.629)0.0512.011 (0.760--5.324)0.159 T35.776 (2.620--12.732)\< 0.0012.996 (1.231--7.292)0.016 T4a13.604 (6.384--28.989)\< 0.0014.944 (1.974--12.383)0.001pN stage\< 0.001\< 0.001 N0RefRef N12.107 (1.122--3.955)0.021.413 (0.704--2.835)0.330 N23.254 (1.887--5.610)\< 0.0011.667 (0.878--3.164)0.118 N38.778 (5.563--13.85)\< 0.0013.557 (1.98--6.392)\< 0.001Tumor size ≤ 5 cmRefRef \> 5 cm2.986 (2.304--3.871)\< 0.0011.314 (0.982--1.758)0.066Histological subtype DifferentiatedRefRef Undifferentiated1.564 (1.120--2.183)0.0091.077 (0.765--1.516)0.672Adjuvant chemotherapy^a^ NoRefRef Yes1.335 (1.025--1.739)0.0320.706 (0.535--0.932)0.014*HR* hazard ratio, *CI* confidence interval, *MGC* multiple gastric cancers, *cT stage* clinical tumor stage, *cN stage* clinical node stage, *cN0* clinical node-negative, *cN+* clinical node-positive, *pT stage* pathological tumor stage, *pN stage* pathological node stage, *Ref* reference^a^*Adjuvant chemotherapy* only the matched 547 patients with advanced gastric cancer were analyzed

Impact of chemotherapy on the survival of advanced MGC patients {#Sec13}
---------------------------------------------------------------

After stratification by adjuvant chemotherapy, the 5-year OS rate of advanced GC (AGC) patients who did not had adjuvant chemotherapy after surgery was found to be 43.4%, of which the 5-year OS rates of the MGC and SGC groups were 34.0% and 46.1%, respectively. This difference in 5-year OS was found to be statistically significant (*P* = 0.025, Fig. [4](#Fig4){ref-type="fig"}a). Regarding those AGC patients who received adjuvant chemotherapy, their overall 5-year survival rate was 52.2%, and the 5-year OS rates for the MGC and SGC groups were 48.0% and 53.3%, respectively, and no statistical difference in survival was observed (*P* = 0.292, Fig. [4](#Fig4){ref-type="fig"}b). Consequently, the 5-year OS rate of patients with advanced MGC was found to be 43.0%, of which the 5-year OS rates of those with adjuvant chemotherapy were significantly higher than those without adjuvant chemotherapy (48.0% vs. 34.0%, respectively; *P* = 0.026, Fig. [4](#Fig4){ref-type="fig"}c).Fig. 4Impact of chemotherapy and advanced MGC on OS. **a** Impact of MGC on the OS of patients without chemotherapy. The 5-year OS rate of AGC patients who did not receive adjuvant chemotherapy was 43.4%. For the MGC and SGC groups, the 5-year OS rates were 34.0% and 46.1%, respectively (*P* = 0.025). **b** Impact of MGC on the OS of patients who had adjuvant chemotherapy. The 5-year OS rate of AGC patients who received adjuvant chemotherapy was 52.2%. For the MGC and SGC groups, the 5-year OS rates were 48.0% and 53.3%, respectively (*P* = 0.292). **c** Impact of adjuvant chemotherapy on the OS of patients with advanced MGC. The 5-year OS rate of patients with advanced MGC was 43.0%, of which the groups with and without adjuvant chemotherapy were 48.0% and 34.0%, respectively (*P* = 0.026). *MGC* multiple gastric cancers, *OS* overall survival

Discussion {#Sec14}
==========

Our study demonstrated that the 5-year OS rate of patients with MGC was 48.1%, which was significantly poorer than those with SGC (58.7%) (*P* = 0.013) and that MGC was an independent risk factor for survival (Hazard ratio \[HR\] = 1.378, 95% confidence interval \[CI\] 1.061--1.870, *P* = 0.039). Further, our results identified that postoperative adjuvant chemotherapy could improve the 5-year OS rate of patients with advanced MGC.

Although most GCs consist of only one single lesion, MGCs are not uncommon. The incidence of MGC in our study was 3.2%. Some scholars believe that MGCs are a special type of GC, and there are differences in clinicopathological characteristics between MGC and SGC. Mitsudomi et al. found that MGCs were more common in elderly men and early GC \[[@CR4]\]. In a study by Otsuji et al., they also found that patients with MGC and SGC had significant differences in tumor size, macroscopic types, depth of invasion, and the extent of lymph node dissection \[[@CR6]\]. However, some scholars also believe that there are similarities between some of the clinicopathological features of MGC and SGC \[[@CR3], [@CR17]--[@CR20]\]. In our study, MGC and SGC had no statistically significant differences in terms of demographic characteristics, such as age, sex, BMI, family history. Regarding postoperative pathology, MGC had deeper depths of invasion, greater number of lymph node metastases, and more advanced pathological stages, suggesting that MGCs may have a more aggressive nature in contrast to SGC.

Currently, there are few studies relating to the prognosis of patients with MGC, but those existing have shown contrasting results. Borie et al. investigated 199 cases of SGC and 33 cases of MGC. Their results showed that the 5-year OS rate of early MGC was greater than 90%, and was comparable to that of early SGC \[[@CR8]\]. But in a study by Maeta et al. who analyzed 2241 cases of SGC and 164 cases of MGC, they found that the long-term prognosis of MGC cases was poorer than those of SGC in both stages I--II and III--IV \[[@CR21]\]. However, these studies had significant differences in their investigated clinicopathological data, between the MGC and SGC groups, which may have led to the observed conflicting findings. In this study, we included a larger number of cases to analyze the clinicopathological differences between MGC and SGC cases, and we used a propensity score matching method to balance the differences between these two groups of patients to further explore the predictors associated with the prognosis for patients with MGC. Our results showed that the 5-year OS rate of MGCs was lower than that of SGCs, and that MGC was an independent predictor for postoperative OS. The reasons to why MGC patients have poor prognosis are still inconclusive. In a study which included 1606 patients who underwent gastrectomy with a follow-up for about 19 years postoperatively, the authors found that patients with MGC were more prone to metachronous cancers in the colon, urogenital system, and other organs than those with SGC \[[@CR22]\]. Therefore, it is possible that patients with MGC may be more susceptible to canceration of other organs due to genetic susceptibility, leading to the poor long-term prognosis. In addition, Eom et al. reported that the prevalence of missed diagnosis of MGC by preoperative endoscopy was as high as 29.5% \[[@CR7]\]. For such cases, if they did not undergo total gastrectomy, they could experience a higher risk postoperative tumor recurrence. Therefore, considerable awareness should be given to the possibility of multifocal cancer in the stomach. The preoperative, intraoperative, and postoperative examination of specimens should be strengthened and meticulously performed to avoid missed diagnoses.

In addition, we investigated the impact that different types of gastrectomy may have on the prognosis of MGC, but our results demonstrated that the type of gastrectomy was not an independent predictor of prognosis for patients with MGC (*P* = 0.114, Fig. [3](#Fig3){ref-type="fig"}d).

Further, this is the first study to have investigated the impact of chemotherapy on the prognosis of MGC. In this study, the 5-year OS rate of advanced MGC patients who received adjuvant chemotherapy was 48.0%. Most patients with advanced GC were recommended to receive 6 to 8 cycles of adjuvant chemotherapy. However, this depended on the patient's performance status, major organ functions, severity of comorbidities and their willingness to comply with implement adjuvant chemotherapy. In clinical practice, we have observed that some proportion of our patients, especially those from rural areas or those who underwent surgery in the past decades, were reluctant to accept or comply with regular visits for postoperative adjuvant chemotherapy as compared to those being diagnosed in the recent years, and we hypothesize that these may have partly contributed to the cause of why some patients with AGC were not adjuvantly treated.

As shown in Fig. [4](#Fig4){ref-type="fig"}, our study found that for AGC patients without adjuvant chemotherapy, the 5-year OS rate of MGC was inferior than that of SGC (34.0% vs. 46.1%, *P* = 0.025), while for those who had adjuvant chemotherapy, the 5-year OS rates of patients with MGC and SGC were comparable (48.0% vs. 53.3%; *P* = 0.292). Further, we found that the 5-year OS rate of advanced MGC patients with adjuvant chemotherapy was significantly higher than those without adjuvant chemotherapy (48.0% vs. 34.0%; *P* = 0.026). The efficacy of adjuvant chemotherapy for AGC has been confirmed by multiple prospective studies. In multicenter studies from Japan and South Korea, the 5-year OS rate of patients receiving adjuvant chemotherapy after surgery was significantly higher than that of patients undergoing radical surgery alone \[[@CR23], [@CR24]\], and similar results were observed in western studies \[[@CR25], [@CR26]\]. In our study, chemotherapy has demonstrated significant survival benefits in patients with advanced MGC, however, the optimal regimen for such category of patients is yet to be determined.

Despite demonstrating the impact of adjuvant chemotherapy on the long-term survival of patients with MGC, the present study has several limitations that need to be addressed. First, the retrospective and non-randomized nature of this study makes it subjective to certain selection bias. Second, since our database only recorded whether the enrolled patients had or did not have adjuvant chemotherapy, data regarding the specific number of chemotherapy cycles were incomplete, and we believe this may have had some impacts on the results obtained, to some extent. Third, since we were unable to obtain accurate data on the type of cancer relapse (local recurrence, peritoneal metastasis, or distant metastasis) from our database, we could not analyze if there was a difference in the type of relapse between MGC and SGC. Fourth, due to the limited cases of MGC in our study, we did not further classify N3 stage as N3a and N3b. Despite these limitations, this study provided a reliable insight on the outcomes of patients with MGC and could be used as a preliminary basis for prospective multicenter studies on the treatment selection for this category of patients.

Conclusions {#Sec15}
===========

In this study, by using propensity score matching analysis to balance the differences between cofounding variables, we have found that MGCs were an independent factor for survival and demonstrated worsen postoperative prognoses as compared to those with SGCs. However, the implementation of postoperative adjuvant chemotherapy to advanced MGC cases demonstrated significant improvement in their long-term survival and should be highly recommended.
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